Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
Skin Cancer01:30

Skin Cancer

4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

ASO Visual Abstract: Comparing Resident Team Performance in Complex Surgical Oncology: A Single-Institution Cohort Study.

Annals of surgical oncology·2026
Same author

Comparing Resident Team Performance in Complex Surgical Oncology: A Single-Institution Cohort Study.

Annals of surgical oncology·2026
Same author

Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.

Cancer immunology research·2026
Same author

Patient selection, practice patterns, and perioperative outcomes for robotic splenectomy: a contemporary ACS-NSQIP analysis.

Surgical endoscopy·2026
Same author

Melanoma-patient-derived xenograft multi-omics resource melPDomiX maps gain- and loss-of-function alterations.

Cell reports·2026
Same author

Marital Status Is Associated With Treatment Attainment in Pancreatic Adenocarcinoma.

Journal of surgical oncology·2026

相关实验视频

Updated: Jul 4, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

435

对于可切除黑色素瘤的新辅助疗法.

Cimarron E Sharon1, Giorgos C Karakousis2

  • 1Department of Surgery, Division of Endocrine and Oncologic Surgery, Hospital of the University of Pennsylvania, Maloney 4 3400 Spruce Street, Philadelphia, PA, 19104, USA. cimarron.sharon@pennmedicine.upenn.edu.

Clinical & experimental metastasis
|January 28, 2024
PubMed
概括

与单独辅助治疗相比,治疗III/IV阶段黑色素瘤的新辅助治疗显示出患者反应的改善和毒性降低. 进一步的研究将根据患者对新辅助疗法的反应来个性化治疗计划.

关键词:
免疫疗法是一种免疫疗法.黑色素瘤是一种黑色素瘤.新辅助疗法是一种新辅助疗法.

更多相关视频

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.4K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K

相关实验视频

Last Updated: Jul 4, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

435
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.4K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K

科学领域:

  • 在瘤学瘤学.
  • 皮肤病学 皮肤病学
  • 临床试验 临床试验

背景情况:

  • 可切除的III/IV阶段黑色素瘤的标准治疗包括手术,然后再进行辅助治疗.
  • 最近的进展为黑色素瘤患者的新辅助使用引入了全身疗法.

研究的目的:

  • 对可切除III/IV期黑色素瘤的新辅助疗法的临床试验进行审查.
  • 确定最佳的新辅助治疗方案,以最大限度地提高患者的反应并最大限度地降低毒性.

主要方法:

  • 对调查黑色素瘤新辅助疗法的临床试验的系统审查.
  • 对治疗结果,患者反应率和毒性概况的分析.

主要成果:

  • 新辅助疗法在可切除的III/IV阶段黑色素瘤中比单独辅助疗法具有优势.
  • 确定了最佳治疗方案,提高了患者的反应,减少了与治疗相关的毒性.

结论:

  • 新辅助疗法是治疗可切除的III/IV阶段黑色素瘤的一个有前途的方法.
  • 未来的研究应该专注于利用对新辅助治疗的反应来预后和个性化治疗计划.